Target intelligence / Profile preview

G protein–coupled estrogen receptor 1 (GPER)

Target
GPER
Molecular classification
G protein–coupled receptor, Receptor
01

Overview

G protein–coupled estrogen receptor 1 (GPER) is a non-classical estrogen receptor, structurally belonging to the G protein–coupled receptor superfamily[1][3][5][7][9]. It is primarily localized to the endoplasmic reticulum and intracellular membranes but can also be found at the plasma membrane[7]. GPER is activated by estradiol and mediates rapid, non-genomic signaling events, including transactivation of epidermal growth factor receptor (EGFR), stimulation of cell proliferative pathways, and anti-apoptotic signaling[2][7][9]. Unlike classical estrogen receptors (ERα and ERβ), which function as nuclear transcription factors, GPER operates through G protein–dependent mechanisms to regulate intracellular cAMP, protein kinase A (PKA), and other downstream kinases such as PI3K/Akt and ERK[7][9]. GPER plays roles in reproductive tissues, the cardiovascular system, metabolism, and the central nervous system[4][5][6][8]. Its expression and activity are implicated in various diseases, notably cancers of the reproductive system, metabolic syndrome, cardiovascular disease, and some neurological conditions[2][4][6][8]. Therapeutically, both agonists and antagonists targeting GPER are under investigation for their potential in oncology, metabolic disorders, and cardiovascular diseases. Endocrine-modulating drugs like Tamoxifen and Fulvestrant, although traditionally considered antagonists of nuclear estrogen receptors, act as agonists at GPER, influencing drug responsiveness and resistance[8]. GPER expression is a prognostic marker in several cancers, and its modulation presents both opportunities and risks in disease therapy, particularly where rapid estrogen signaling contributes to pathology[2][8].

Other names
G protein–coupled receptor 30GPR30GPER1
02

Mechanism of action

Agonists: Activate rapid, non-genomic cell signaling via GPER (increase cAMP, activate EGFR, stimulate PI3K/Akt, ERK, promote cell proliferation, survival, metabolic regulation) Antagonists: Block estrogen-induced rapid signaling, may inhibit cancer cell proliferation or prevent metabolic effects

03

Biological functions

Signal transductionCell proliferationCell survival (anti-apoptotic signaling)Regulation of glucose toleranceImmune modulation (anti-inflammatory)Cardiovascular function regulation
04

Disease associations

Cancer (breast, endometrial, ovarian, prostate)Cardiovascular diseaseObesityDiabetesVascular pathologyNeurodegenerative diseaseSchizophrenia
05

Safety considerations

Potential for unwanted widespread tissue effects due to ubiquitous expressionCancer proliferation/aggravation with certain GPER agonists (e.g. Tamoxifen in some breast cancer settings)Unclear/variable effect in different tissues (sex-differential outcomes in cardiovascular and neurological models)
06

Interacting drugs

Tamoxifen (agonist at GPER)

6 more in the full profile.

07

Biomarkers

GPER expression levels (prognostic and predictive, e.g. in breast and endometrial cancer)Correlation with poor survival in endometrial and ovarian cancer

Beyond the preview

Go deeper on G protein–coupled estrogen receptor 1 (GPER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G protein–coupled estrogen receptor 1 (GPER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call